Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Mitochondrial apoptosis pathway proteins" refers collectively to a set of key regulatory and effector proteins that mediate the intrinsic, mitochondria-driven form of programmed cell death known as apoptosis. This is not a single molecule but a functional group comprising several well-characterized components: Core components include: - Bcl‑2 family proteins: These regulate mitochondrial outer membrane permeabilization. Pro-apoptotic members like Bax and Bak promote membrane disruption; anti-apoptotic members like Bcl‑2 itself inhibit it.[3][5][6] - Cytochrome c: Released from mitochondria upon apoptotic signaling, it binds with Apaf‑1 and ATP to form the apoptosome complex.[1] - Apaf‑1: Acts as an adaptor forming the apoptosome with cytochrome c, which then activates initiator caspase‑9. - Caspases: Caspase‑9 is activated by the apoptosome; downstream effector caspases such as caspase‑3 execute cellular demolition.[1] - Other IMS-resident proapoptotic factors include Smac/DIABLO, Omi/HtrA2, AIF, endonuclease G.[7] This pathway plays essential roles in normal development, tissue homeostasis, immune regulation, and removal of damaged cells. Dysregulation contributes directly to diseases including cancer—where resistance to mitochondrial apoptosis underlies treatment failure—as well as neurodegeneration and cardiovascular disorders.[5][6] Therapeutically relevant drugs often target individual components—most notably inhibitors against anti-apoptotic Bcl‑2 family members are used clinically for certain cancers. However, "mitochondrial apoptosis pathway proteins" is too broad for precise drug targeting or biomarker use; specificity at the level of individual molecules is required for clinical application. Because this entry refers generically to a *group* rather than a single molecular entity—and because each component has distinct properties—the entry should be considered incorrect/incomplete if used where only one canonical target should be specified. For structured data purposes it would be preferable instead to refer specifically by name—for example "B-cell lymphoma 2", "Cytochrome c", or "Apoptotic protease activating factor 1". The mitochondrial intermembrane space houses diverse proapoptotic factors whose regulated release triggers formation of multiprotein complexes that activate downstream executioner enzymes leading irreversibly toward cell death—a process central both for normal physiology and many pathologies including cancer resistance mechanisms.[7][3][5]
Induction of mitochondrial outer membrane permeabilization to trigger cytochrome c release and caspase activation – Inhibition of anti-apoptotic Bcl‑2 family proteins to promote cell death in cancer cells
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial apoptosis pathway protein (null).